A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.Blood · 2008
   Trial
2. Digging deep into "dirty" drugs - modulation of the methylation machinery.Drug metabolism reviews · 2015
   Review
3. Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.Leukemia · 2014
   Article
4. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
   Article
5. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies.Seminars in oncology · 2012
   Review
6. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.Pharmacogenomics · 2011
   Article
7. Retraction. A microarray study of altered gene expression in Ara-C resistance in acute myeloid leukemia.Leukemia · 2010
   Article
8. Genetic factors influencing cytarabine therapy.Pharmacogenomics · 2009
   Review
9. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.Blood · 2009
   Article

Corrections and comments

• Retraction · 2010-08-01Error in Analyses · Error in Cell Lines/Tissues · Retract and Replace ·
• Retracted
  Retraction. A microarray study of altered gene expression in Ara-C resistance in acute myeloid leukemia.2010

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as